RU2636032C2 - Применение антитела i-3859 для выявления и диагностики рака - Google Patents

Применение антитела i-3859 для выявления и диагностики рака Download PDF

Info

Publication number
RU2636032C2
RU2636032C2 RU2014103054A RU2014103054A RU2636032C2 RU 2636032 C2 RU2636032 C2 RU 2636032C2 RU 2014103054 A RU2014103054 A RU 2014103054A RU 2014103054 A RU2014103054 A RU 2014103054A RU 2636032 C2 RU2636032 C2 RU 2636032C2
Authority
RU
Russia
Prior art keywords
cxcr4
sequence
seq
cdr
antibody
Prior art date
Application number
RU2014103054A
Other languages
English (en)
Russian (ru)
Other versions
RU2014103054A (ru
Inventor
Кристин КЛИНГЕР-АМУР
Александра ЖУАННО
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of RU2014103054A publication Critical patent/RU2014103054A/ru
Application granted granted Critical
Publication of RU2636032C2 publication Critical patent/RU2636032C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2014103054A 2011-07-29 2012-07-30 Применение антитела i-3859 для выявления и диагностики рака RU2636032C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
US61/513,345 2011-07-29
EP11306000.8 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (2)

Publication Number Publication Date
RU2014103054A RU2014103054A (ru) 2015-09-10
RU2636032C2 true RU2636032C2 (ru) 2017-11-17

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014103054A RU2636032C2 (ru) 2011-07-29 2012-07-30 Применение антитела i-3859 для выявления и диагностики рака

Country Status (14)

Country Link
US (1) US20140170677A1 (enExample)
EP (1) EP2736926A1 (enExample)
JP (1) JP6138780B2 (enExample)
KR (1) KR20140047127A (enExample)
CN (1) CN103717620A (enExample)
AR (1) AR087363A1 (enExample)
AU (2) AU2012292116A1 (enExample)
BR (1) BR112014001979A2 (enExample)
CA (1) CA2842552A1 (enExample)
IL (1) IL230693A0 (enExample)
MX (1) MX2014001160A (enExample)
RU (1) RU2636032C2 (enExample)
WO (1) WO2013017562A1 (enExample)
ZA (1) ZA201400500B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271422A (zh) * 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
ES2837015T3 (es) * 2015-10-23 2021-06-29 Novartis Ag Sistema de derivación de proximidades espaciales entre células
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP4005598A1 (en) 2016-03-29 2022-06-01 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
CN109414504B (zh) 2016-03-29 2022-04-08 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CA3080821A1 (en) * 2017-11-07 2019-05-16 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
WO2019200223A1 (en) * 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EA010163B1 (ru) * 2003-05-02 2008-06-30 Полифор Аг СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308996A1 (en) * 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010163B1 (ru) * 2003-05-02 2008-06-30 Полифор Аг СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
CA2842552A1 (en) 2013-02-07
EP2736926A1 (en) 2014-06-04
WO2013017562A1 (en) 2013-02-07
ZA201400500B (en) 2014-11-26
US20140170677A1 (en) 2014-06-19
JP6138780B2 (ja) 2017-05-31
CN103717620A (zh) 2014-04-09
RU2014103054A (ru) 2015-09-10
JP2014523920A (ja) 2014-09-18
AU2012292116A1 (en) 2014-02-06
BR112014001979A2 (pt) 2017-02-21
AR087363A1 (es) 2014-03-19
IL230693A0 (en) 2014-03-31
AU2017204043A1 (en) 2017-07-06
MX2014001160A (es) 2014-07-14
KR20140047127A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
RU2636345C2 (ru) Новое антитело к cxcr4 и его применение для выявления и диагностики рака
JP6138780B2 (ja) 癌の検出および診断のための抗体ｉ−３８５９の使用
US20100215573A1 (en) Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
TW201311726A (zh) 抗體ｉ－３８５９用於癌症偵測及診斷之用途
OA18453A (en) IGF-1R antibody and its use for the diagnosis of cancer
HK1243434B (zh) Igf-1r抗体及其诊断癌症的用途
HK1183311A (en) Novel antibody for the diagnosis and/or prognosis of cancer

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180731